Search Results - "Lamy, P. J."

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial by Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C.

“…IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. This…”
Get full text

Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses by Soorojebally, Y, Neuzillet, Y, Lebret, T, Allory, Y, Descotes, F, Ferlicot, S, Kassab-Chahmi, D, Lamy, P-J, Oudard, S, Rébillard, X, Roy, C, Roumiguié, M, Rouprêt, M, Audenet, F

“…Currently, bladder cancer detection is based on cytology and cystoscopy. White light cystoscopy (WLC) is an invasive procedure and may under-detect flat…”
Get more information

Serum protein signature may improve detection of ductal carcinoma in situ of the breast by Solassol, J, Rouanet, P, Lamy, P J, Allal, C, Favre, G, Maudelonde, T, Mangé, A

“…Ductal carcinoma in situ (DCIS) of the breast is part of a spectrum of preinvasive lesions that originate within normal breast tissue and progress to invasive…”
Get full text

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer by JACOT, W, PUJOL, J-L, BOHER, J-M, LAMY, P-J

“…This retrospective study aimed at evaluating the prognostic impact of high serum levels of either the HER-2 extracellular domain (ECD) or the epidermal growth…”
Get full text

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study by Jacot, W, Firmin, N, Roca, L, Topart, D, Gallet, S, Durigova, A, Mirr, S, Abach, L, Pouderoux, S, D'Hondt, V, Bleuse, J P, Lamy, P J, Romieu, G

“…A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level. This…”
Get full text

Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer by LAMY, P.-J, NANNI, I, FINA, F, BIBEAU, F, ROMAIN, S, DUSSERT, C, PENAULT LLORCA, F, GRENIER, J, OUAFIK, Lh, MARTIN, P.-M

“…There is an increasing demand for the evaluation of HER2 status in breast cancer. In this study, sections from fixed tissues and triton extracts of tissue…”
Get full text

P31 Abdominal obesity and prostate cancer risk: results from the EPICAP study by Lavalette, C, Cordina Duverger, E, Cénée, S, Rebillard, X, Lamy, PJ, Trétarre, B, Menegaux, F

“…BackgroundObesity is associated with an increased risk of several cancers, but the relationship between obesity and prostate cancer (PCa) remains…”
Get full text

OP110 Body mass index trajectories and prostate cancer risk in the EPICAP study by Lavalette, C, Cordina Duverger, E, Cénée, S, Rebillard, X, Lamy, PJ, Trétarre, B, Menegaux, F

“…BackgroundHigh body mass index (BMI) has been inconsistently associated with prostate cancer (PCa) risk. Recent studies suggest that BMI trajectory modeling…”
Get full text

Analysis of the potential contribution of estrogen receptor (ER) β in ER cytosolic assay of breast cancer by Brouillet, J.P., Dujardin, M.A., Chalbos, D., Rey, J.M., Grenier, J., Lamy, P.J., Maudelonde, T., Pujol, P.

“…Estrogen receptor (ER) content is the most useful parameter for predicting hormone response therapy in breast cancer. Assays available for detecting ER in…”
Get full text

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? by Lopez-Crapez, E, Mineur, L, Emptas, H, Lamy, P-J

Get full text

The PSA caught out by Gauchez, A-S, Lamy, P J, Descotes, J L

“…With the widespread use of prostate specific antigen (PSA) prescription and despite the automatization of PSA assessment, clinicians should not forget the…”
Get more information

UPA/PAI-1: a tool for breast cancer treatment individualization. Biology, clinical implications and quantification assays by Lamy, P-J, Romieu, G, Jacot, W

“…The several options for therapy in breast cancer underline the difficulties to determine the reliable population which can be treated by a specific adjuvant…”
Get more information

uPA/PAI-1 : un outil d’individualisation de la prise en charge des cancers du sein. Biologie, implications cliniques et méthodes de dosage by Lamy, P.-J., Romieu, G., Jacot, W.

“…Les multiples possibilités thérapeutiques des cancers du sein contrastent avec la difficulté actuelle de déterminer avec fiabilité la population la plus à même…”
Get full text

Traitement par iode 131 des cancers thyroïdiens différenciés : recommandations 2017 des sociétés françaises SFMN/SFE/SFP/SFBC/AFCE/SFORL by Zerdoud, S., Leboulleux, S., Clerc, J., Leenhardt, L., Bournaud, C., Al Ghuzlan, A., Keller, I., Bardet, S., Giraudet, A.-L., Groussin, L., Sebag, F., Garrel, R., Lamy, P.-J., Toubert, M.-E., Mirallié, É., Hindié, E., Taïeb, D.

Get full text

Imagerie moléculaire et biomarqueurs des cancers thyroïdiens de souche vésiculaire : recommandations 2017 de SFMN/SFE/SFP/SFBC/AFCE/SFORL by Giraudet, A.-L., Bardet, S., Toubert, M.-E., Lamy, P.-J., Zerdoud, S., Leboulleux, S., Clerc, J., Leenhardt, L., Bournaud, C., Al Ghuzlan, A., Keller, I., Groussin, L., Sebag, F., Garrel, R., Mirallié, E., Taïeb, D., Hindié, E.

Get full text

Septième Symposium bioclinique « Biomarqueurs du cancer de la prostate : innovations et perspectives by Lamy, P.-J., Gauchez, A.-S.

Get full text

Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer by Lamy, P.-J., Nanni, I., Fina, F., Bibeau, F., Romain, S., Dussert, C., Penault Llorca, F., Grenier, J., Ouafik, L'H, Martin, P.-M.

Get full text

Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer by Lamy, Pierre-Jean, Grenier, Jean, Kramar, Andrew, Pujol, Jean-Louis

“…Background: Small cell lung cancer (SCLC) yields neuroendocrine properties. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE) and…”
Get full text

PP52 Amplification of the chromosome 17 q22 amplicon containing TOP2A gene is correlated with better survival in HER2 amplified/hormone receptors negative breast cancers by Lamy, P.-J, Fina, F, Servanton, A.-C, Dussert, C, Ouafik, L'H, Jacot, W, Martin, P.-M

Get full text

Measles Virus Exploits Dendritic Cells to Suppress CD4+ T-Cell Proliferation via Expression of Surface Viral Glycoproteins Independently of T-Cell Trans-infection by Dubois, Bertrand, Lamy, Pierre Jean, Chemin, Karine, Lachaux, Alain, Kaiserlian, Dominique

“…Dendritic cells (DC) have been proposed to play a pivotal role in transient immune suppression induced by measles virus (MV) infection. In the present study,…”
Get full text